News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
381,697 Results
Type
Article (25921)
Company Profile (59)
Press Release (355717)
Multimedia
Podcasts (25)
Webinars (7)
Section
Business (104260)
Career Advice (449)
Deals (16873)
Drug Delivery (51)
Drug Development (47600)
Employer Resources (47)
FDA (12262)
Job Trends (8440)
News (185930)
Policy (19422)
Tag
Academia (1750)
Accelerated approval (3)
Adcomms (8)
Allergies (73)
Alliances (26744)
ALS (57)
Alzheimer's disease (811)
Antibody-drug conjugate (ADC) (51)
Approvals (12326)
Artificial intelligence (168)
Autoimmune disease (10)
Automation (4)
Bankruptcy (142)
Best Places to Work (6892)
BIOSECURE Act (5)
Biosimilars (36)
Biotechnology (39)
Bladder cancer (59)
Brain cancer (17)
Breast cancer (192)
Cancer (1429)
Cardiovascular disease (119)
Career advice (407)
Career pathing (13)
CAR-T (69)
Cell therapy (198)
Cervical cancer (13)
Clinical research (40513)
Collaboration (439)
Compensation (126)
Complete response letters (9)
COVID-19 (1493)
CRISPR (12)
C-suite (139)
Cystic fibrosis (42)
Data (1521)
Decentralized trials (2)
Denatured (17)
Depression (30)
Diabetes (174)
Diagnostics (3520)
Digital health (11)
Diversity (5)
Diversity, equity & inclusion (13)
Drug discovery (52)
Drug pricing (54)
Drug shortages (21)
Duchenne muscular dystrophy (55)
Earnings (36908)
Editorial (20)
Employer branding (6)
Employer resources (44)
Events (51792)
Executive appointments (447)
FDA (13243)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (3)
Frontotemporal dementia (3)
Funding (401)
Gene editing (36)
Generative AI (10)
Gene therapy (126)
GLP-1 (400)
Government (3034)
Grass and pollen (3)
Guidances (40)
Healthcare (12186)
Huntington's disease (10)
IgA nephropathy (16)
Immunology and inflammation (40)
Indications (19)
Infectious disease (1563)
Inflammatory bowel disease (79)
Inflation Reduction Act (4)
Influenza (26)
Intellectual property (50)
Interviews (40)
IPO (7039)
IRA (19)
Job creations (1839)
Job search strategy (378)
Kidney cancer (7)
Labor market (10)
Layoffs (169)
Leadership (4)
Legal (3632)
Liver cancer (57)
Lung cancer (232)
Lymphoma (100)
Machine learning (3)
Management (17)
Manufacturing (104)
MASH (47)
Medical device (12904)
Medtech (12907)
Mergers & acquisitions (10123)
Metabolic disorders (430)
Multiple sclerosis (54)
NASH (11)
Neurodegenerative disease (49)
Neuropsychiatric disorders (9)
Neuroscience (1142)
NextGen: Class of 2025 (3930)
Non-profit (2822)
Now hiring (16)
Obesity (217)
Opinion (70)
Ovarian cancer (52)
Pain (63)
Pancreatic cancer (53)
Parkinson's disease (88)
Partnered (11)
Patents (112)
Patient recruitment (80)
Peanut (37)
People (34713)
Pharmaceutical (17)
Pharmacy benefit managers (11)
Phase I (11605)
Phase II (17534)
Phase III (14413)
Pipeline (680)
Policy (59)
Postmarket research (1668)
Preclinical (3617)
Press Release (18)
Prostate cancer (76)
Psychedelics (17)
Radiopharmaceuticals (160)
Rare diseases (183)
Real estate (2846)
Recruiting (16)
Regulatory (14207)
Reports (16)
Research institute (1608)
Resumes & cover letters (48)
Rett syndrome (2)
RNA editing (2)
RSV (20)
Schizophrenia (50)
Series A (65)
Series B (48)
Service/supplier (3)
Sickle cell disease (21)
Special edition (3)
Spinal muscular atrophy (102)
Sponsored (13)
Startups (2120)
Stomach cancer (8)
Supply chain (38)
Tariffs (11)
The Weekly (8)
Vaccines (351)
Venture capitalists (13)
Weight loss (141)
Women's health (17)
Worklife (4)
Date
Today (89)
Last 7 days (450)
Last 30 days (1439)
Last 365 days (18522)
2025 (5859)
2024 (19850)
2023 (22740)
2022 (30681)
2021 (32987)
2020 (32194)
2019 (28415)
2018 (21811)
2017 (18908)
2016 (18111)
2015 (21194)
2014 (16024)
2013 (13241)
2012 (14350)
2011 (14623)
2010 (13184)
Location
Africa (354)
Alabama (17)
Alaska (2)
Arizona (117)
Arkansas (10)
Asia (24549)
Australia (3887)
California (3046)
Canada (1216)
China (371)
Colorado (164)
Connecticut (172)
Delaware (113)
Europe (47939)
Florida (541)
Georgia (126)
Idaho (33)
Illinois (358)
India (14)
Indiana (223)
Iowa (3)
Japan (119)
Kansas (73)
Kentucky (12)
Louisiana (7)
Maine (27)
Maryland (633)
Massachusetts (2130)
Michigan (107)
Minnesota (270)
Mississippi (2)
Missouri (52)
Montana (18)
Nebraska (18)
Nevada (33)
New Hampshire (60)
New Jersey (1122)
New Mexico (9)
New York (949)
North Carolina (553)
North Dakota (4)
Northern California (1332)
Ohio (131)
Oklahoma (3)
Oregon (23)
Pennsylvania (822)
Puerto Rico (7)
Rhode Island (24)
South America (521)
South Carolina (20)
Southern California (1168)
Tennessee (77)
Texas (535)
United States (12739)
Utah (111)
Virginia (79)
Washington D.C. (39)
Washington State (228)
West Virginia (3)
Wisconsin (42)
381,697 Results for "setpoint medical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
SetPoint Medical Announces Late-Breaking Data from RESET-RA Study at ACR Convergence 2024
November 18, 2024
·
5 min read
FDA
SetPoint Medical Receives FDA Breakthrough Device Designation for its Neuroimmune Modulation Platform for the Treatment of Multiple Sclerosis
SetPoint Medical Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel neuroimmune modulation platform for people living with relapsing-remitting multiple sclerosis (RRMS).
March 13, 2024
·
4 min read
Press Releases
SetPoint Medical Announces Filing of Premarket Approval (PMA) Application to the U.S. Food and Drug Administration (FDA) for Novel Neuroimmune Modulation Device for the Treatment of Rheumatoid Arthritis
December 9, 2024
·
2 min read
Policy
SetPoint Medical Accepted into FDA Total Product Life Cycle Advisory Program for Development of its Neuroimmune Modulation Platform for the Treatment of Multiple Sclerosis
SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced that it has been accepted into the Total Product Life Cycle Advisory Program Pilot from the U.S. Food and Drug Administration for the development of its novel neuroimmune modulation platform for people living with relapsing-remitting multiple sclerosis.
March 21, 2024
·
3 min read
Press Releases
SetPoint Medical Receives FDA’s IDE Approval for U.S. Pilot Study of Neuroimmune Modulation Platform in Adults with Relapsing-Remitting Multiple Sclerosis
October 2, 2024
·
3 min read
Business
SetPoint Medical Appoints Rohan Seth as Chief Financial Officer
SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced the appointment of Rohan Seth as Chief Financial Officer.
June 12, 2023
·
2 min read
Biotech Beach
SetPoint Medical Announces Publication of Data for Neuroimmune Modulation to Treat Crohn’s Disease in Journal of Crohn’s and Colitis
SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, today announced the publication of data from a multicenter European clinical trial evaluating the safety and efficacy of neuroimmune modulation in patients with treatment-refractory Crohn’s disease in the Journal of Crohn’s and Colitis.
October 3, 2023
·
3 min read
Press Releases
SetPoint Medical Announces Positive Topline Results from Landmark RESET-RA Study Evaluating Neuroimmune Modulation for the Treatment of Rheumatoid Arthritis
July 10, 2024
·
5 min read
Biotech Beach
SetPoint Medical Announces $80M Preferred Stock Financing to Advance Company’s Novel Treatment for Autoimmune Diseases
SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, today announced an $80 million preferred stock financing co-led by new investors Norwest Venture Partners and Viking Global Investors.
January 19, 2023
·
3 min read
Biotech Bay
SetPoint Medical Announces Expanded $65M Credit Facility to Support Development of the Company’s Novel Platform for Rheumatoid Arthritis
SetPoint Medical today announced a senior secured term loan facility of up to $65 million from Runway Growth Capital LLC (“Runway”), a leading provider of growth loans to both venture and non-venture backed companies.
January 19, 2023
·
3 min read
1 of 38,170
Next
